J. Baselga

Abstract S6-01: <i>PIK3CA</i> status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2– advanced breast cancer (BC): First results from the randomized, phase III BELLE-2 trial

J. Baselga, S-A. Im, Hiroji Iwata et al. · Cancer Research · 2016 · 88 citations

Tumor Biology, Endocrine Oncology, Breast Oncology +15

Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer

Aleix Prat, Marta Parera, Sergio Peralta et al. · Annals of Oncology · 2007 · 61 citations

Medicine, Cancer Management, Nadir Ca-125 Concentration +8

687 Beta-catenin Confers Resistance to PI3K and AKT Inhibitors and Subverts FOXO3a to Promote Metastasis in Colon Cancer

Stephan P. Tenbaum, Paloma Ordóñez‐Morán, Isabel Puig et al. · European Journal of Cancer · 2012 · 52 citations

Tumor Biology, Subverts Foxo3a, Gastrointestinal Oncology +10

Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels

Aleix Prat, Marta Parera, Bárbara Adamo et al. · Annals of Oncology · 2008 · 34 citations · Full text

Cancer Risk, Cancer Epidemiology, Medicine +11

Fat embolism syndrome following bone marrow harvesting.

J. Baselga, L Reich, Mark Doherty et al. · PubMed · 1991 · 19 citations